Pipeline

Print page

Scynexis Pipeline Chart

SCYNEXIS has developed two independent technologies enabling the discovery of novel anti-infective drugs. The initial application of these technologies, antifungal and anti-viral drug discovery, has delivered clinical development candidates for invasive fungal infections and hepatitis C.

SCYNEXIS has built discovery and development expertise around these technologies to progress the current lead compounds through clinical development in humans, and to identify next generation compounds for use in the anti-infective field, including a new treatment for dry eye disease currently in development for animal health. SCYNEXIS’ technology is supported by a number of issued and pending patents covering both composition-of-matter and use applications.

SCYNEXIS has collaborated with partners to identify three clinical stage compounds for animal health use. Among these compounds, one is in development for canine dry eye (keratoconjunctivitis sicca, or KCS) with Dechra Pharmaceuticals PLC and two anti-parasitic compounds have resulted from an extended collaboration with Merial.

A further SCYNEXIS collaboration with Drugs for Neglected Diseases initiative (DNDi) and funded by the Bill & Melinda Gates Foundation, led to a new treatment for stage 2 African sleeping sickness that is currently in Phase 1 studies.

SCY-078, the first compound from the Enfumafungin anti-fungal platform, is in Phase 2 studies for invasive fungal infections (IFI).

SCY-635, the first compound from the cyclophilin inhibitors anti-viral platform, has just completed Phase 2a clinical studies for the treatment of Hepatitis C (HCV).

SCY-641, the first compound from the calcineurin inhibitors platform, is in preclinical studies for human health and is entering Phase 3 clinical studies for animal health. This compound was recently licensed to Dechra Pharmaceuticals PLC, a UK-listed international veterinary pharmaceutical business for development and commercialization for the treatment of canine keratoconjunctivitis sicca (KCS).

Additionally, SCYNEXIS has two other compounds for animal health in late clinical development with Merial, a division of Sanofi.